Adrian Towse : Citation Profile


Are you Adrian Towse?

Office of Health Economics

8

H index

6

i10 index

165

Citations

RESEARCH PRODUCTION:

15

Articles

46

Papers

13

Books

RESEARCH ACTIVITY:

   24 years (1994 - 2018). See details.
   Cites by year: 6
   Journals where Adrian Towse has often published
   Relations with other researchers
   Recent citing documents: 13.    Total self citations: 19 (10.33 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pto443
   Updated: 2021-03-01    RAS profile: 2018-04-23    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Hampson, Grace (9)

Berdud, Mikel (4)

Karlsberg Schaffer, Sarah (3)

Karlsberg, Sarah (3)

Garau, Martina (3)

Cubi-Molla, Patricia (2)

Cole, Amanda (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Adrian Towse.

Is cited by:

Devlin, Nancy (7)

Garau, Martina (6)

Cole, Amanda (5)

Hampson, Grace (5)

Shah, Koonal (4)

Neri, Margherita (3)

Forster, Martin (2)

Graf von der Schulenburg, Johann (2)

Tsuchiya, Aki (2)

O'Neill, Phill (2)

Pammolli, Fabio (2)

Cites to:

Devlin, Nancy (13)

Danzon, Patricia (9)

Rice, Nigel (7)

Claxton, Karl (6)

Szymanski, Stefan (6)

Valletti, Tommaso (6)

Shah, Koonal (6)

Parkin, David (6)

Lakdawalla, Darius (5)

Garau, Martina (5)

Philipson, Tomas (5)

Main data


Where Adrian Towse has published?


Journals with more than one article published# docs
The European Journal of Health Economics4
Health Economics4
Health Policy2
International Journal of the Economics of Business2
PharmacoEconomics2

Working Papers Series with more than one paper published# docs
Briefings / Office of Health Economics14
Consulting Reports / Office of Health Economics13
Research Papers / Office of Health Economics10
Occasional Papers / Office of Health Economics6

Recent works citing Adrian Towse (2021 and 2020)


YearTitle of citing document
2021Overcoming inefficiencies in the development of personalized medicine. (2021). Wuttke, David A ; Heese, Sebastian H ; Lutkemeyer, Daniel. In: European Journal of Operational Research. RePEc:eee:ejores:v:290:y:2021:i:1:p:278-296.

Full description at Econpapers || Download paper

2020Regenerative medicine regulatory policies: A systematic review and international comparison. (2020). Toumi, Mondher ; Borislav, Borisov ; Dabbous, Monique ; Hanna, Eve ; Qiu, Tingting. In: Health Policy. RePEc:eee:hepoli:v:124:y:2020:i:7:p:701-713.

Full description at Econpapers || Download paper

2020Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D. (2020). Sanzenbacher, Geoffrey ; Wettstein, Gal. In: Journal of Health Economics. RePEc:eee:jhecon:v:72:y:2020:i:c:s0167629619305703.

Full description at Econpapers || Download paper

2020Association between provincial income levels and drug prices in China over the period 2010–2017. (2020). Yang, Xiuyun ; Mossialos, Elias ; Liu, Gordon ; Wouters, Olivier J ; Shi, Wunan. In: Social Science & Medicine. RePEc:eee:socmed:v:263:y:2020:i:c:s0277953620304664.

Full description at Econpapers || Download paper

2020A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance. (2020). Mott, David ; Hopkins, Michael M ; Mestre-Ferrandiz, Jorge ; Llewelyn, Martin J ; Hampson, Grace. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:1:d:10.1007_s40258-019-00516-0.

Full description at Econpapers || Download paper

2020Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea. (2020). Kim, Hyero ; Han, Euna ; Lee, Hye-Jae. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:4:d:10.1007_s40258-019-00547-7.

Full description at Econpapers || Download paper

2020Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review. (2020). Ghabri, Salah ; Bousquet, Philippe Jean ; Bouee-Benhamiche, Elsa. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:4:d:10.1007_s40258-020-00562-z.

Full description at Econpapers || Download paper

2020The impact of prescription drug co-payments for publicly insured families. (2020). Nolan, Anne ; Mohan, Gretta. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:21:y:2020:i:2:d:10.1007_s10198-019-01125-3.

Full description at Econpapers || Download paper

2020Should health technology assessment be more patient centric? If so, how?. (2020). Tarricone, Rosanna ; Torbica, Aleksandra ; Drummond, Michael. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:21:y:2020:i:8:d:10.1007_s10198-020-01182-z.

Full description at Econpapers || Download paper

2020HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. (2020). Shah, Koonal ; Graf von der Schulenburg, Johann ; Shen, Jie ; Durand-Zaleski, Isabelle ; Ratcliffe, Mark ; Coyle, Doug ; Pemberton-Whiteley, Zack ; Palmer, Stephen ; Moutie, Anne-Sophie ; Meunier, Aurelie ; Longworth, Louise ; Greiner, Wolfgang ; Zhao, Kun ; Garrison, Louis ; Sproule, Doug ; Farrington, Jasmine. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:21:y:2020:i:9:d:10.1007_s10198-020-01212-w.

Full description at Econpapers || Download 2020

Keeping Pace with Pharmaceutical Innovation: The Importance of the NICE Methods Review. (2020). Catchpole, Paul ; Barrett, Victoria. In: PharmacoEconomics. RePEc:spr:pharme:v:38:y:2020:i:9:d:10.1007_s40273-020-00918-2.

Full description at Econpapers || Download paper

2020Incentivizing New Veterinary Pharmaceutical Products to Combat Antibiotic Resistance. (2020). Clancy, Matt ; Sneeringer, Stacy. In: Applied Economic Perspectives and Policy. RePEc:wly:apecpp:v:42:y:2020:i:4:p:653-673.

Full description at Econpapers || Download paper

2020Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model. (2020). Hicks, Meagen ; Taie, Amer ; Lumley, Matthew ; McEwan, Phil ; Darlington, Oliver ; Wilcox, Mark ; Gordon, Jason ; Otter, Jonathan ; Goldenberg, Simon ; Hawkins, Neil ; Blake, Angela ; Charbonneau, Claudie. In: PharmacoEconomics. RePEc:spr:pharme:v:38:y:2020:i:8:d:10.1007_s40273-020-00906-6.

Full description at Econpapers || Download

Works by Adrian Towse:


YearTitleTypeCited
2017Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation In: Health Policy.
[Full Text][Citation analysis]
article2
1999Is disease management relevant in Europe: some evidence from the United Kingdom In: Health Policy.
[Full Text][Citation analysis]
article0
2011Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement In: NBER Working Papers.
[Full Text][Citation analysis]
paper10
2015Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement.(2015) In: Health Economics.
[Full Text][Citation analysis]
This paper has another version. Agregated cites: 10
article
2012Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context In: NBER Working Papers.
[Full Text][Citation analysis]
paper13
2015Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context.(2015) In: Health Economics.
[Full Text][Citation analysis]
This paper has another version. Agregated cites: 13
article
2014What is the Role of HTA for Biosimilars? In: Briefings.
[Full Text][Citation analysis]
paper0
2008The Market for Biosimilars: Evolution and Policy Options In: Briefings.
[Full Text][Citation analysis]
paper5
2006Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds In: Briefings.
[Full Text][Citation analysis]
paper0
1997Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry In: Briefings.
[Full Text][Citation analysis]
paper2
1998From Efficacy to Cost-Effectiveness In: Briefings.
[Full Text][Citation analysis]
paper0
2003Reducing Harm to Patients in the National Health Service. Will the Governments Compensation Proposals Help? In: Briefings.
[Full Text][Citation analysis]
paper1
2016How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes? In: Briefings.
[Full Text][Citation analysis]
paper0
2017Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies In: Briefings.
[Full Text][Citation analysis]
paper0
2017How can HTA meet the needs of health system and government decision makers? In: Briefings.
[Full Text][Citation analysis]
paper0
2017Transferability of HTA In: Briefings.
[Full Text][Citation analysis]
paper0
2017HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers? In: Briefings.
[Full Text][Citation analysis]
paper0
2017Incentives for New Drugs to Tackle Anti-Microbial Resistance In: Briefings.
[Full Text][Citation analysis]
paper0
2017Additional Elements of Value for Health Technology Assessment Decisions In: Briefings.
[Full Text][Citation analysis]
paper1
2017Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? In: Briefings.
[Full Text][Citation analysis]
paper0
2014The Expanding Value Footprint of Oncology Treatments In: Consulting Reports.
[Full Text][Citation analysis]
paper3
2011The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response In: Consulting Reports.
[Full Text][Citation analysis]
paper3
2010Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2009Assessment and Appraisal of Oncology Medicines: NICEs Approach and International HTA Experience In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2006Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2015Data Governance Arrangements for Real-World Evidence In: Consulting Reports.
[Full Text][Citation analysis]
paper2
2016Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making In: Consulting Reports.
[Full Text][Citation analysis]
paper2
2016Four Case Studies to Explore the Added Value of Oxford AHSN In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2016Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2017Policy Options for Formulary Development in Middle-income Countries In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2017Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose? In: Consulting Reports.
[Full Text][Citation analysis]
paper3
2018Review of CRAs Report Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2018Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2012The R&D Cost of a New Medicine In: Monographs.
[Full Text][Citation analysis]
book8
2011New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options In: Monographs.
[Full Text][Citation analysis]
book1
2010Biosimilars: How Much Entry and Price Competition Will Result? In: Monographs.
[Full Text][Citation analysis]
book0
2008The Ideas and Influence of Alan Williams: Be Reasonable – Do It My Way In: Monographs.
[Full Text][Citation analysis]
book1
2006Economic Post-Launch Studies: Matching the Desirable with the Feasible In: Monographs.
[Full Text][Citation analysis]
book1
1995Financing Health Care in the UK: A Discussion of NERAs Prototype Model to Replace the NHS In: Monographs.
[Full Text][Citation analysis]
book1
1995Industrial Policy and the Pharmaceutical Industry In: Monographs.
[Full Text][Citation analysis]
book0
1995Value of the Pharmaceutical Industry to the UK Economy In: Monographs.
[Full Text][Citation analysis]
book0
1997Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada? In: Monographs.
[Full Text][Citation analysis]
book1
1999Disease Management, the NHS and the Pharmaceutical Industry In: Monographs.
[Full Text][Citation analysis]
book0
2002Cost-Effectiveness Thresholds: Economic and ethical issues In: Monographs.
[Full Text][Citation analysis]
book13
2002Influencing Prescribing in a Primary Care Led NHS In: Monographs.
[Full Text][Citation analysis]
book0
2002Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty In: Monographs.
[Full Text][Citation analysis]
book3
2013Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold In: Occasional Papers.
[Full Text][Citation analysis]
paper8
2012The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation? In: Occasional Papers.
[Full Text][Citation analysis]
paper2
2011Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Papers.
[Full Text][Citation analysis]
paper2
2010New Drugs to Tackle Antimicrobial Resistance: EU Policy Options In: Occasional Papers.
[Full Text][Citation analysis]
paper1
2014Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies? In: Occasional Papers.
[Full Text][Citation analysis]
paper0
2015International Decision Support Initiative (iDSI): Mapping of priority-setting in health in 17 low and middle countries across Asia, Latin America, and Africa In: Occasional Papers.
[Full Text][Citation analysis]
paper0
2013Exploring the link between health and wealth in decision making In: Research Papers.
[Full Text][Citation analysis]
paper0
2012Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? In: Research Papers.
[Full Text][Citation analysis]
paper4
2011Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches In: Research Papers.
[Full Text][Citation analysis]
paper0
2011Incentives for R&D for New Antimicrobial Drugs In: Research Papers.
[Full Text][Citation analysis]
paper0
2011Incentives for R&D for New Antimicrobial Drugs.(2011) In: International Journal of the Economics of Business.
[Full Text][Citation analysis]
This paper has another version. Agregated cites: 0
article
2010Using QALYs in Cancer: Review of the Methodological Limitations In: Research Papers.
[Full Text][Citation analysis]
paper8
2016Uncertainty and Risk in HTA Decision Making In: Research Papers.
[Full Text][Citation analysis]
paper1
2017Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value In: Research Papers.
[Full Text][Citation analysis]
paper2
2017Macro Evaluation of the NIHR Oxford Biomedical Research Centre In: Research Papers.
[Full Text][Citation analysis]
paper0
2018Real World Evidence for Coverage Decisions: Opportunities and Challenges In: Research Papers.
[Full Text][Citation analysis]
paper4
2018Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions In: Research Papers.
[Full Text][Citation analysis]
paper0
2015Multi-indication Pricing: Pros, Cons and Applicability to the UK In: Seminar Briefings.
[Full Text][Citation analysis]
paper3
2016Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria In: Oxford Review of Economic Policy.
[Full Text][Citation analysis]
article0
2012Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article10
2014Orphan drugs policies: a suitable case for treatment In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article10
2004Genetic screening, health care and the insurance industry In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article2
2006The desirability and feasibility of economic studies of drugs post-launch In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article1
2013Operationalizing Value-Based Pricing of Medicines In: PharmacoEconomics.
[Full Text][Citation analysis]
article11
2016Biosimilars: How Can Payers Get Long-Term Savings? In: PharmacoEconomics.
[Full Text][Citation analysis]
article7
2015European Union Pharmaceutical Markets: A Case for Differential Pricing? In: International Journal of the Economics of Business.
[Full Text][Citation analysis]
article5
1994The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0?333?58579?8 In: Health Economics.
[Full Text][Citation analysis]
article0
1999Medical negligence and the NHS: an economic analysis In: Health Economics.
[Full Text][Citation analysis]
article6

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated November, 2 2021. Contact: CitEc Team